close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

42.36 -1.09 (-2.50%)
Streaming Delayed Price Updated: 10:35 AM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More
While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7. 
Via Stocktwits
FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use
Agios' Pyrukynd FDA review for thalassemia delayed to Dec. 7, 2025, after REMS submission addressing potential liver injury risk. 
Via Benzinga
Top movers in Thursday's pre-market session
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns
Via Stocktwits
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
An Overview of Agios Pharmaceuticals's Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Traders are paying attention to the gapping stocks in Monday's session.
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Earnings Scheduled For February 13, 2025
 
Via Benzinga
Analyst Ratings For Agios Pharmaceuticals
 
Via Benzinga
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
What's going on in today's pre-market session
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Agios (AGIO) Q2 Revenue Jumps 45%
Via The Motley Fool
Topics Intellectual Property
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Mixed Q2 2025 Results: Revenue Beat but Wider EPS Loss
Agios Pharmaceuticals (AGIO) reported Q2 2025 revenue of $12.46M, beating estimates, but EPS of -$1.93 missed forecasts. Shares fell 10.66% pre-market amid mixed financials and ongoing rare disease... 
Via Chartmill
Earnings Preview: Agios Pharmaceuticals
 
Via Benzinga
4 Analysts Have This To Say About Agios Pharmaceuticals
 
Via Benzinga
Expert Ratings For Agios Pharmaceuticals
 
Via Benzinga
Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years
Agios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results. 
Via Benzinga
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug
The company is currently seeking approval for its thalassemia treatment in four regions. 
Via Investor's Business Daily
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
 
Via Benzinga
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides
Agios Pharmaceuticals' Phase 3 ACTIVATE-KidsT study results reveal that mitapivat achieved a 28.1% transfusion reduction in children with PK deficiency compared to 11.8% with placebo. Secondary... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today